Hepatocerebral degeneration, also known as Wilson's disease, is an inherited disorder associated with impaired copper metabolism in the body. It is characterized by the accumulation of copper in the liver and central nervous system, leading to the development of various disorders of both the liver and the nervous system. Patients may experience symptoms such as jaundice, cognitive impairment, movement disorders, and mental disorders. The disease usually begins at a young age and can lead to severe complications, including cirrhosis of the liver and progressive neurological disorders.
History of the disease and interesting historical facts
Hepatocerebral degeneration was first described in the early 20th century. In 1912, Hungarian physician Henrik Wilson published the results of his study, in which he recorded symptoms similar to those observed in modern patients with Wilson's disease. Since then, the disease has been actively studied, and in the 1940s, a link was established between copper metabolism disorders and the development of this syndrome. An interesting historical fact is that the disease remained undiagnosed for a long time due to the variety of clinical manifestations.
Epidemiology
Hepatocerebral degeneration has a prevalence of about 1 in 30,000 to 100,000 people in the population, but the actual figures may vary depending on the ethnic group. For example, people of European descent have a higher incidence than some other races. The disease usually appears between the ages of 5 and 35, but in rare cases it can be found in children and the elderly.
Genetic predisposition to this disease
The genetic basis of hepatocerebral degeneration is associated with mutations in the ATP7B gene, which is responsible for copper transport in cells. Most cases of the disease are caused by an autosomal recessive type of inheritance, which requires two copies of the defective gene to develop symptoms. More than 700 different mutations in the ATP7B gene have been identified, making diagnostics and genetic testing important tools for identifying predisposition to the disease and its early detection.
Risk factors for the development of this disease
Among the known risk factors that contribute to the development of hepatocerebral degeneration, the following are distinguished:
- Heredity: Having close relatives with the diagnosis indicates a high risk of the disease.
- Gender: The disease is more common in men, although women are also at risk.
- Environmental factors: An unfavorable environmental situation can aggravate symptoms if there is a genetic predisposition.
- Diet: Deficiency of copper in the diet and other dietary factors may influence the course of the disease.
Diagnosis of this disease
Diagnosis of hepatocerebral degeneration is based on clinical manifestations and laboratory tests. The main symptoms include:
- Jaundice and changes in liver function tests.
- Neurological disorders such as tremors, dystonia and cognitive impairment.
- Mental disorders, including depression and personality changes.
Laboratory tests, such as serum copper measurement and ceruloplasmin levels, play a key role in the diagnosis. Radiologic examinations, including brain MRI, may reveal neuroimaging changes characteristic of the disease. The differential diagnosis includes exclusion of other liver diseases and neurologic disorders with similar symptoms.
Treatment
Treatment for hepatocerebral degeneration is aimed at reducing copper levels in the body and eliminating the symptoms that result from its accumulation. The main treatment methods include:
- General treatment: follow a low copper diet.
- Pharmacological treatment: use of copper chelators such as dimerin and pensilamine, which promote the removal of copper from the body.
- Surgical treatment: In severe cases, a liver transplant may be required.
- Other types of treatment: therapy for mental and neurological disorders that arise against the background of the disease.
List of medications used to treat this disease
Among the drugs used to treat hepatocerebral degeneration, the following are distinguished:
- Pensilamine is a copper chelator that promotes its elimination.
- Trientine is another drug that lowers copper levels in the body.
- Zinc sulfate - used to block copper absorption in the intestines.
Disease monitoring
Monitoring of hepatocerebral degeneration includes regular checkpoints such as blood tests for copper and ceruloplasmin levels, as well as assessment of the functional state of the liver and the patient's neurological status. The prognosis of the disease varies depending on the timely initiation of treatment; without adequate control, the disease can lead to serious complications, including acute liver failure and progressive neurological dysfunction.
Age-related features of the disease
Hepatocerebral degeneration manifests itself differently depending on the patient's age. In children, the disease may manifest itself more acutely, with pronounced neurological symptoms. Adult patients often demonstrate a combination of liver and neurological symptoms. In older people, the course of the disease may not be as pronounced, but they are still at risk of complications.
Questions and Answers
- What are the main symptoms of hepatocerebral degeneration? The main symptoms include jaundice, neurological disorders (tremor, dystonia), mental disorders and liver enlargement.
- Can hepatocerebral degeneration be cured? A complete cure is not possible, but treatment can significantly improve quality of life and slow the progression of the disease.
- What is the role of genetic testing in diagnosis? Genetic testing helps identify mutations in the ATP7B gene and allows for early diagnosis.
- How often should patients with this disease be examined? Regular check-ups should be performed at least every 6 months to monitor copper levels and assess liver function.
- Can stress affect disease symptoms? Yes, stress can worsen existing symptoms and cause flare-ups of the disease.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends remembering the importance of early diagnosis of hepatocerebral degeneration. “Understanding that in the early stages of the disease, its progress can be slowed down with simple lifestyle changes and drug therapy is extremely important.” He also says that stress should be avoided and a low-copper diet should be followed. In addition, regular medical examinations play a critical role in monitoring the state of health and the adequacy of the treatment.
